Early prediction of clinical response to first-line treatment with gefitinib using integrated FDG-PET for patients with advanced non-small cell lung cancer.

e18049 Background: Early prediction of clinical response is of great value in patients with advanced non-small cell lung cancer (NSCLC) in avoiding unnecessary toxicity and giving them another chance for different treatment. This study aimed to assess the integrated 18-fluorodeoxyglucose positron emission tomography (FDG-PET) at 3 days after treatment as a tool for early response predictor in the patients treated with gefitinib or carboplatin plus paclitaxel (CP). Methods: Patients with stage IIIB or IV NSCLC were scheduled to receive first-line treatment were eligible for this study. Patients were treated with gefitinib (250mg) once daily or with CP every 3-week cycle as first-line treatment. FDG-PET was performed before and 3 day after initiation of each treatment. Based on previous studies, a reduction of tumor FDG uptake was assessed by using standardized uptake value (SUV). ROC analyses were performed to compare the results of the visually interpreted FDG-PET findings and the findings obtained with t...